Xingping Su‡
a,
Zhihao Liu‡a,
Lin Yuea,
Xiuli Wua,
Wei Weia,
Hanyun Quea,
Tinghong Yea,
Yi Luo*b and
Yiwen Zhang*a
aSichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. E-mail: yiwenzhang@scu.edu.cn
bDepartment of Orthopedics, West China Hospital of Sichuan University, Wai Nan Guo Xue Xiang 37#, 610041, Chengdu, Sichuan, China. E-mail: orthop_luoyi@163.com
First published on 9th June 2021
Abnormal activation of FGFR signaling pathway plays an essential role in various types of tumors. Therefore, targeting FGFRs represents an attractive strategy for cancer therapy. Herein, we report a series of 1H-pyrrolo[2,3-b]pyridine derivatives with potent activities against FGFR1, 2, and 3. Among them, compound 4h exhibited potent FGFR inhibitory activity (FGFR1–4 IC50 values of 7, 9, 25 and 712 nM, respectively). In vitro, 4h inhibited breast cancer 4T1 cell proliferation and induced its apoptosis. In addition, 4h also significantly inhibited the migration and invasion of 4T1 cells. Furthermore, 4h with low molecular weight would be an appealing lead compound which was beneficial to the subsequent optimization. In general, this research has been developing a class of 1H-pyrrolo[2,3-b]pyridine derivatives targeting FGFR with development prospects.
Abnormal activation of FGFR signaling pathway due to amplification, fusion or missense mutations in the exon of FGFR family members is associated with the progression and development of several cancers such as breast cancer, lung cancer, prostate cancer, bladder cancer and liver cancer.10–14 Moreover, activation of FGFR-dependent signaling pathways can facilitate cancer initiation, progression, and resistance to cancer therapy. Hence, the FGFR signaling pathway is an important and proven target for cancer therapeutics. Currently, FGFR inhibitors are currently under clinical investigation for the treatment of various cancers such as AZD4547,15 JNJ-42756493 (Erdafitinib),16 CH5183184,17 BGJ-398,18 LY2874455,19 INCB054828 (Pemigatinib)20 and so on, shown in Fig. 1. Recently, FDA has announced approval of Erdafitinib21 and Pemigatinib.22
During the development of our FGFR inhibitor program, we wish to explore a novel and concise scaffold of selective FGFR inhibitors. Based on previous literature studies, we found that compound 1 has potent FGFR1 inhibitory activity with IC50 value of 1.9 μM (ref. 23) (Fig. 2A). Compared with the existing FGFR inhibitors, compound 1 contains a novel core scaffold 1H-pyrrolo[2,3-b]pyridine with low molecular mass and high ligand efficiency. Jin Q. et al. developed a series of 1H-pyrrolo[2,3-b]pyridine derivatives as FGFR4 inhibitors with potent antiproliferative activity against Hep3B cells.24 Furthermore, 1H-pyrrolo[2,3-b]pyridine also as a new scaffold used in other targets research, such as human neutrophil elastase (HNE).25 Moreover, recent studies have shown that 1H-pyrrolo[2,3-b]pyridine analogues have inhibitory activity against different cancer cell lines.26
We firstly investigated the co-crystallization structure (PDB code 3C4F) to understand interactions between 1 and FGFR1 kinase domain (Fig. 2B). As a hinge binder, 1H-pyrrolo[2,3-b]pyridine ring of 1 could form two hydrogen bonds with the backbone carbonyl of E562 and NH of A564 in the hinge region. The methoxyphenyl motif could potentially occupy hydrophobic pocket in the ATP site and form van der Waals interactions with amino acid residues of the hydrophobic pocket, and its methoxy group could also form a strong hydrogen bond with the NH of D641.
Based on above analyses, to quest for a novel and concise chemotype of FGFR inhibitors, we kept 1H-pyrrolo[2,3-b]pyridine motif as hinge binder and focused on utilizing structure-based design strategy to design 1H-pyrrolo[2,3-b]pyridine derivatives as potent FGFR inhibitors. Given that the 5-position of 1H-pyrrolo[2,3-b]pyridine is close to G485, a group which could provide hydrogen bond acceptor with suitable size was introduced into the 5-position of 1H-pyrrolo[2,3-b]pyridine ring to form a hydrogen bond with G485 to improve the activity. Meanwhile, the m-methoxyphenyl fragment was altered to various larger substituents to explore the possible interactions within the hydrophobic pocket. In this study, we report the synthesis and biology evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as potent FGFR inhibitors.
The synthesis of all compounds is shown in Scheme 1. The starting material 5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine was reacted with R-substituted aldehyde at 50 °C to obtain the compounds 3a–3k in 45–60% yield. Subsequently, 3a–3k in the presence of acetonitrile under triethylsilane and trifluoroacetic acid catalysis at reflux to undergo a reduction reaction to furnish 4a–4l in 46–80%.
All prepared compounds were screened for their inhibitory activity against FGFR1 at the concentration of 0.1 and 1 μM as well as antiproliferative activities against 4T1 (mouse breast cancer cells), MDA-MB-231 and MCF-7 cancer cells at 10 μM. As summarized in Tables 1 and 2, compound 1 with low molecular mass demonstrated FGFR1 potency with an IC50 value of 1900 nM. Based on our analysis above, a suitably sized trifluoromethyl was introduced at the 5-position of the 1H-pyrrolo[2,3-b]pyridine ring (4a) in 1 to form hydrogen bond with G485. Remarkably, the activity against FGFR1 of 4a increased nearly 20-fold compared with compound 1, implying that our strategy was feasible. Then the m-methoxy moiety of 4a was modified to improve FGFR activities. The methoxy group at the 3-position of phenyl ring in 4a replaced with chlorine (4b) decreased FGFR1 potency and cellular activity. Poor activities of 4b may be due to the weak electronegativity of Cl atom in 4b which cannot form strong hydrogen bond with D641. Introduction of 3-trifluoromethyl group at the 3-position of phenyl ring reduced the activities of 4c, which may be result from the inability of trifluoromethyl group to form a hydrogen bond with the NH of D641. The introduction of suitable group at the 3-position of phenyl ring to occupy the hydrophobic pocket improved the FGFR1 activity (4a–e), indicating a suitable size of the group on this position was favorable. Incorporation of a trifluoromethyl (4f) or benzyloxy (4g) at the 4-position of phenyl ring declined both FGFR1 and cellular activities. Then the influence of substituents on 3- and 5-positions of the phenyl ring 4a was investigated. Excitingly, introduction of methoxy groups at the 3- and 5-positions significantly improved against FGFR1 potency (4h) (95% & 0.1 μM) and cellular activity (4T1) (57% & 10 μM). However, multiple substitutions at other positions (4i, 4j, 4k, 4l) exhibited declined FGFR1 and cellular activities. In addition, the presence of a hydroxyl also decreased FGFR1 potency and cellular activity (4a vs. 3a), (4h vs. 3h) which implicated that the hydroxyl group may be too close to its neighboring amino acid F489, resulting in decreased activities.
Compound | R | FGFR1 inhibition rate (%) | Inhibition rate 10 μM (%) | |||
---|---|---|---|---|---|---|
1 μM | 0.1 μM | 4T1 | MDA-MB-231 | MCF-7 | ||
a Cell results are given in concentrations of 10 μM after a continuous exposure of 72 h and show means ± SD of two-independent experiments. NS: not significant; NT: not tested. | ||||||
1 | — | 55 | 7 | 11 ± 0.02 | 8 ± 2.14 | 16 ± 0.62 |
3a | ![]() |
78 | 35 | 16 ± 0.01 | 6 ± 1.22 | 33 ± 0.50 |
3b | ![]() |
25 | 1 | NS | 10 ± 2.88 | 14 ± 3.18 |
3c | ![]() |
22 | 22 | NS | 23 ± 0.63 | 33 ± 0.71 |
3d | ![]() |
22 | −5 | NS | 12 ± 1.50 | 21 ± 0.82 |
3e | ![]() |
34 | 15 | NS | NS | 26 ± 0.88 |
3f | ![]() |
25 | 14 | NS | 18 ± 0.70 | 33 ± 1.10 |
3g | ![]() |
25 | −1 | NS | 28 ± 0.23 | 25 ± 1.05 |
3h | ![]() |
89 | 61 | 23 ± 0.01 | 13 ± 3.80 | 33 ± 0.11 |
3i | ![]() |
61 | 19 | NS | 21 ± 1.87 | 32 ± 1.24 |
3j | ![]() |
17 | 3 | NS | 15 ± 0.97 | 30 ± 1.17 |
3k | ![]() |
11 | 3 | NT | NT | NT |
Compound | R | FGFR1 inhibition rate (%) | Inhibition rate 10 μM (%) | |||
---|---|---|---|---|---|---|
1 μM | 0.1 μM | 4T1 | MDA-MB-231 | MCF-7 | ||
a Cell results are given in concentrations of 10 μM after a continuous exposure of 72 h and show means ± SD of two-independent experiments. NS: not significant. | ||||||
4a | ![]() |
91 | 53 | 18 ± 0.01 | 15 ± 1.16 | 32 ± 0.54 |
4b | ![]() |
56 | 2 | NS | 6.1 ± 0.16 | 29 ± 0.83 |
4c | ![]() |
19 | 10 | 26 ± 0.04 | 29 ± 0.24 | 51 ± 0.17 |
4d | ![]() |
21 | 15 | NS | 25 ± 0.36 | 27 ± 3.33 |
4e | ![]() |
64 | 21 | NS | 16 ± 0.54 | 26 ± 1.65 |
4f | ![]() |
21 | 24 | 17 ± 0.02 | 20 ± 2.60 | 44 ± 0.73 |
4g | ![]() |
29 | −4 | NS | 25 ± 2.44 | 32 ± 0.24 |
4h | ![]() |
91 | 95 | 57 ± 0.01 | 22 ± 0.08 | 33 ± 0.94 |
4i | ![]() |
78 | 29 | NS | 14 ± 3.18 | 41 ± 0.71 |
4j | ![]() |
16 | 7 | 13 ± 0.02 | 19 ± 0.38 | 46 ± 1.09 |
4k | ![]() |
40 | 19 | 22 ± 0.03 | 20 ± 0.03 | 46 ± 0.49 |
4l | ![]() |
76 | 27 | 23 ± 0.01 | 9 ± 0.62 | 22 ± 1.66 |
Compound 3h, 4a, 4h and 4l were selected to investigate their inhibitory activities against other FGFR isoforms, including FGFR1, FGFR2, FGFR3 and FGFR4 (Table 3). All these compounds exhibited inhibitory activities to FGFR1–3 in vitro. Among them, 4h showed the best activities that effectively inhibited the activities of FGFR1–4 with IC50 values of 7, 9, 25 and 712 nM, respectively. Based on above results, 4h was chosen for further biological evaluation.
Compound | IC50 (nM) | |||
---|---|---|---|---|
FGFR1 | FGFR2 | FGFR3 | FGFR4 | |
3h | 54 | 66 | 320 | >3000 |
4a | 83 | 93 | 421 | >3000 |
4h | 7 | 9 | 25 | 712 |
4l | 266 | 259 | 634 | >3000 |
AZD-4547 | 0.8 | 1 | 2 | 47 |
To investigate the binding modes of our inhibitors, compound 4h was docked with FGFR1 protein, as showed in Fig. 3. The nucleus 1H-pyrrolo[2,3-b]pyridine could form two hydrogen bonds with the backbone carbonyl of E562 and NH of A564 in the hinge region. In addition, the essential π–π interaction was observed between 3,5-dimethoxyphenyl of 4h and F489. Then, the 3,5-dimethoxyphenyl group could more fully and appropriately occupy the hydrophobic pocket and maintain the formation of hydrogen bonds with D641. As expected, trifluoromethyl substitution at the 5-position of 1H-pyrrolo[2,3-b]pyridine could form a hydrogen bond with G485, which may be a crucial factor in improving the activity of the compound. In addition, the ligand efficiency of 4h (LE = 0.44) has been significantly improved compared with compound 1 (LE = 0.13).
To further investigate whether 4h could inhibit the proliferation of 4T1 cells, we conducted the colony formation assays. As showed in Fig. 4, the colony formation of 4T1 cells was reduced after treatment with 4h. Moreover, 4h could inhibit the population-dependence growth of 4T1 cells. These results suggest that 4h could inhibit 4T1 cells viability in a concentration-dependent manner.
To quantify whether the anti-survival activity of 4h in 4T1 cells was related to apoptosis. We analyzed the level of apoptosis by FCM using the Annexin V–FITC/PI double labelling technique. As Fig. 5A indicated, the 4h could induce 4T1 cells apoptosis compared with vehicle after treatment with 4h for 24 h. Then we performed western blot analysis to further characterize 4h-induced apoptosis (Fig. 5B). The expression level of anti-apoptotic protein Bcl2 was decreased, whereas the proapoptotic protein cleaved caspase-3 was increased in a dose-dependent manner after 4h treatment in 4T1 cells. These data suggest that 4h could induce 4T1 cell apoptosis.
Next, we used FCM to detect the change of Δψm after staining with the fluorescent dye Rh123. As showed in Fig. 6A, treatment with 4h for 24 h resulted in a loss of Δψm in 4T1 cells. Furthermore, we examined the ROS level by FCM using the DCFH-DA indicator (Fig. 6B). The results showed that the level of ROS in 4T1 cells increased after treatment with 4h for 24 h. These data indicated that 4h was able to induce apoptosis of 4T1 cell, and it might be via the mitochondrial apoptosis pathway.
Furthermore, we evaluated the effect of compound 4h on the migration and invasion abilities of 4T1 cells through the transwell chamber assay. As showed in Fig. 7, 4h significantly reduced the migration and invasion abilities of 4T1 cells after treatment of 4h for 24 h. Compared to the control group, 4T1 cells migration was inhibited by 36.1%, 77.3%, and 93.8% following treatment with 3.3, 10 and 30 μM 4h, respectively (Fig. 7A). Similarly, 4T1 cells also exhibited significantly decreased invasion in the presence of 4h compared to control group (Fig. 7B). Furthermore, we detected the expression level of several key proteins by western blot. After 4h interfered with 4T1 cells for 24 h, the expression of MMP9 decreased with the increase of 4h concentration, while the expression of TIMP2 gradually increased (Fig. 7C). The results implied that 4h could enhance inhibition of migration and invasion of 4T1 cells which associated with down-regulation of MMP9 and up-regulation of TIMP2.
In conclusion, we discovered a series of 1H-pyrrolo[2,3-b]pyridine derivatives as potent FGFR inhibitors. Structure optimization of 1 led to the identification of 4h, which had pan-FGFR inhibitory activities against FGFR1–4 (IC50 values of 7, 9, 25 and 712 nM, respectively) and nearly 300-fold higher FGFR1 activity than compound 1, showing a highly ligand efficiency (ligand efficiency increased from 0.13 to 0.44). Accordingly, we selected compound 4h for further biological activity evaluation, and the results showed that 4h could inhibit proliferation, induce apoptosis, and significantly inhibit the migration and invasion of 4T1 cells. These data indicated that low molecular weight 4h would be a promising lead compound with a large optimization space for further drug development.
3b: 1H NMR (400 MHz, DMSO-d6) δ 12.04 (s, 1H), 8.53 (d, J = 2.2 Hz, 1H), 8.18 (d, J = 2.2 Hz, 1H), 7.55–7.42 (m, 3H), 7.42–7.34 (m, 2H), 6.04 (d, J = 4.6 Hz, 1H), 5.96 (d, J = 4.6 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 150.52, 144.45, 139.79, 139.75, 131.73, 128.51, 128.47, 126.21, 125.55, 125.51, 119.74, 117.88–116.60 (m), 117.27, 68.15. HRMS m/z (ESI) calcd for C15H11N2OF3Cl [M + H]+: 327.0507, found: 327.0513.
3c: 1H NMR (400 MHz, DMSO-d6) δ 12.07 (s, 1H), 8.53 (d, J = 2.4 Hz, 1H), 8.19 (d, J = 2.2 Hz, 1H), 7.87 (s, 1H), 7.74 (d, J = 7.4 Hz, 1H), 7.63–7.53 (m, 2H), 7.50 (d, J = 1.8 Hz, 1H), 6.15 (d, J = 4.6 Hz, 1H), 6.10 (d, J = 4.6 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 150.51, 146.94, 139.80, 130.80, 129.55 (d, J = 19.5 Hz), 130.17–128.56 (m), 126.93, 126.35, 125.46 (d, J = 3.9 Hz), 124.01 (d, J = 4.0 Hz), 122.94 (d, J = 3.9 Hz), 119.44, 117.26 (q, J = 31.3 Hz), 117.18, 68.16. HRMS m/z (ESI) calcd for C16H11N2OF6 [M + H]+: 361.0770, found: 361.0770.
3d: 1H NMR (400 MHz, chloroform-d) δ 9.83 (s, 1H), 8.57 (d, J = 2.1 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 7.47–7.36 (m, 3H), 7.24–7.15 (m, 2H), 6.20–6.15 (m, 1H); 13C NMR (101 MHz, chloroform-d) δ 150.10, 149.53, 145.00, 140.68, 130.04, 126.17, 125.91, 125.00, 124.73, 123.22, 120.37, 118.98, 118.67, 117.46, 69.63, 29.71. HRMS m/z (ESI) calcd for C16H11N2O2F6 [M + H]+: 377.0719, found: 377.0684.
3e: 1H NMR (400 MHz, DMSO-d6) δ 12.10–11.96 (m, 1H), 8.53 (d, J = 2.1 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 7.35 (m, J = 7.9, 6.2, 3.4 Hz, 3H), 7.25–7.18 (m, 1H), 7.17–7.08 (m, 2H), 7.01–6.93 (m, 2H), 6.89 (m, J = 8.1, 2.6, 1.1 Hz, 1H), 6.01 (d, J = 4.6 Hz, 1H), 5.91 (d, J = 4.6 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 157.21, 156.94, 150.52, 147.86, 139.72, 139.68, 130.39, 130.16, 126.98, 126.27, 125.52 (d, J = 3.8 Hz), 124.28, 123.79, 121.94, 119.79, 118.88, 117.81–116.51 (m), 68.44. HRMS m/z (ESI) calcd for C21H16N2O2F3 [M + H]+: 385.1158, found: 385.1156.
3f: 1H NMR (400 MHz, DMSO-d6) δ 12.08 (s, 1H), 8.53 (d, J = 2.2 Hz, 1H), 8.20 (d, J = 2.3 Hz, 1H), 7.70 (s, 4H), 7.50 (d, J = 2.4 Hz, 1H), 6.23–6.03 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 162.75, 150.49, 150.15, 139.81, 128.08, 127.77, 127.32, 126.95, 126.40, 126.16, 125.47, 124.25, 123.46, 119.38, 117.27 (q, J = 31.5 Hz), 68.26. HRMS m/z (ESI) calcd for C16H11N2OF6 [M + H]+: 361.0770, found: 361.0767.
3g: 1H NMR (400 MHz, methanol-d4) δ 8.45 (d, J = 2.1 Hz, 1H), 8.13 (d, J = 2.3 Hz, 1H), 7.40–7.32 (m, 2H), 7.33–7.21 (m, 6H), 7.10 (t, J = 2.1 Hz, 1H), 7.06 (dt, J = 8.1, 1.0 Hz, 1H), 7.02–6.87 (m, 2H), 6.05 (s, 1H), 5.07 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 158.08, 149.06, 144.43, 138.33, 136.45, 128.21, 127.19, 126.56, 126.24, 124.94, 124.86, 118.24, 118.03, 117.29–116.69 (m), 113.08, 112.04, 68.73, 68.49. HRMS m/z (ESI) calcd for C22H18N2O2F3 [M + H]+: 399.1315, found: 399.1305.
3h: 1H NMR (400 MHz, DMSO-d6) δ 12.04 (s, 1H), 8.53 (d, J = 2.2 Hz, 1H), 8.18 (d, J = 2.2 Hz, 1H), 7.55–7.42 (m, 3H), 7.42–7.34 (m, 2H), 6.04 (d, J = 4.6 Hz, 1H), 5.96 (d, J = 4.6 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 150.52, 144.45, 139.79, 139.75, 131.73, 128.93, 128.73, 128.51, 128.47, 126.21, 125.55, 125.51, 119.74, 117.34, 117.27, 117.03, 68.15. HRMS m/z (ESI) calcd for C17H16N2O3F3 [M + H]+: 353.1108, found: 353.1108.
3i: 1H NMR (400 MHz, DMSO-d6) δ 12.10 (s, 1H), 8.55 (d, J = 2.2 Hz, 1H), 8.28 (d, J = 2.2 Hz, 1H), 7.49 (dd, J = 6.2, 3.1 Hz, 1H), 7.39 (d, J = 2.5 Hz, 1H), 7.26–7.07 (m, 2H), 6.24 (d, J = 4.9 Hz, 1H), 6.11 (dd, J = 5.0, 1.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 159.96, 157.59 (d, J = 2.0 Hz), 156.70 (d, J = 2.2 Hz), 154.30, 150.37, 139.87 (d, J = 3.8 Hz), 134.43 (dd, J = 16.1, 7.0 Hz), 126.42, 125.28 (d, J = 4.0 Hz), 124.27, 118.07, 117.30, 115.64 (d, J = 24.3 Hz), 114.52 (d, J = 20.2 Hz), 62.54. HRMS m/z (ESI) calcd for C15H10N2OF5 [M + H]+: 329.0708, found: 329.2583.
3j: 1H NMR (400 MHz, DMSO-d6) δ 12.10 (s, 1H), 8.55 (d, J = 2.2 Hz, 1H), 8.25 (d, J = 2.2 Hz, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.75 (dd, J = 8.3, 2.1 Hz, 1H), 7.72–7.63 (m, 1H), 7.50 (d, J = 2.4 Hz, 1H), 6.26–6.09 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.51, 145.57, 139.93, 139.89, 132.31, 131.93, 129.37, 129.35, 126.53, 125.75, 125.70, 125.48, 125.44, 119.06, 118.09–116.25 (m), 67.57. HRMS m/z (ESI) calcd for C16H10N2OF6Cl [M + H]+: 395.0380, found: 395.0367.
3k: 1H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 1H), 8.53 (d, J = 2.1 Hz, 1H), 8.24 (d, J = 2.1 Hz, 1H), 7.56–7.41 (m, 2H), 7.39–7.27 (m, 2H), 6.05 (d, J = 10.5 Hz, 2H). 13C NMR (101 MHz, chloroform-d) δ 150.14, 144.08, 143.37, 140.46, 139.05, 131.67, 129.13, 126.24, 125.06, 123.22, 121.63, 118.75, 117.58, 109.29, 108.00, 69.88. HRMS m/z (ESI) calcd for C16H10N2O3F5 [M + H]+: 373.0606, found: 373.0583.
4b: 1H NMR (400 MHz, DMSO-d6) δ 12.00 (s, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.24 (d, J = 2.2 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.33 (s, 4H), 4.13–4.09 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.36, 140.50, 139.69, 139.65, 130.99, 130.72, 128.72, 126.95, 124.76, 124.72, 121.65, 118.60, 117.17 (q, J = 31.3 Hz), 114.30, 30.24. HRMS m/z (ESI) calcd for C15H11N2F3Cl [M + H]+: 311.0557, found: 311.0593.
4c: 1H NMR (400 MHz, DMSO-d6) δ 12.02 (s, 1H), 8.53 (d, J = 2.1 Hz, 1H), 8.30 (d, J = 2.1 Hz, 1H), 7.72 (s, 1H), 7.68–7.57 (m, 2H), 7.57–7.46 (m, 2H), 4.23 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.35, 143.04, 139.69, 133.08, 129.85, 129.69, 129.38, 127.07, 125.37 (d, J = 3.9 Hz), 124.84 (d, J = 3.7 Hz), 123.16 (d, J = 4.1 Hz), 118.56, 117.80–116.16 (m), 114.00, 30.58. HRMS m/z (ESI) calcd for C16H11N2F6 [M + H]+: 345.0821, found: 345.0833.
4d: 1H NMR (400 MHz, DMSO-d6) δ 12.01 (s, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.25 (d, J = 2.1 Hz, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.48–7.29 (m, 3H), 7.17 (d, J = 8.1 Hz, 1H), 4.18 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.37, 148.90, 144.39, 139.65, 130.66, 128.08, 126.97, 124.84, 121.36, 118.88, 118.54, 117.21 (q, J = 31.5 Hz), 113.95, 55.34, 30.62. HRMS m/z (ESI) calcd for C16H11N2OF6 [M + H]+: 361.0770, found: 361.0784.
4e: 1H NMR (400 MHz, DMSO-d6) δ 12.06–11.90 (m, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.19 (d, J = 2.1 Hz, 1H), 7.54 (d, J = 2.3 Hz, 1H), 7.38–7.25 (m, 3H), 7.14–7.06 (m, 2H), 7.03–6.89 (m, 3H), 6.81 (dd, J = 8.2, 2.4 Hz, 1H), 4.11 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 157.17, 157.02, 150.36, 143.77, 139.63, 130.39, 127.04, 126.88, 124.74, 124.18, 123.72, 119.27, 118.78, 118.63, 117.13 (q, J = 31.3 Hz), 116.71, 114.33, 30.85. HRMS m/z (ESI) calcd for C21H16N2OF3 [M + H]+: 369.1209, found: 369.1253.
4f: 1H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 1H), 8.54 (d, J = 2.1 Hz, 1H), 8.36 (d, J = 2.1 Hz, 1H), 7.86 (s, 1H), 7.61 (dd, J = 6.8, 1.9 Hz, 3H), 4.22 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.33, 146.47, 139.74, 129.64, 127.36, 127.16, 127.04, 126.21, 125.65, 124.75, 124.33, 118.61, 117.24 (d, J = 31.3 Hz), 113.78, 30.67. HRMS m/z (ESI) calcd for C16H11N2F6 [M + H]+: 345.0821, found: 345.0839.
4g: 1H NMR (400 MHz, DMSO-d6) δ 11.96 (s, 1H), 8.52 (d, J = 2.2 Hz, 1H), 8.24 (d, J = 2.1 Hz, 1H), 7.51 (d, J = 2.2 Hz, 1H), 7.42–7.28 (m, 4H), 7.19 (t, J = 7.9 Hz, 1H), 7.03–6.94 (m, 1H), 6.89 (d, J = 7.6 Hz, 1H), 6.83 (s, 1H), 5.05 (s, 2H), 4.07 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 158.88, 150.37, 143.05, 139.56, 137.56, 129.83, 128.80, 128.08, 126.81, 124.76, 121.40, 118.71, 117.09 (q, J = 31.3 Hz), 115.62, 114.56, 112.63, 69.54, 31.02. HRMS m/z (ESI) calcd for C22H18N2OF3 [M + H]+: 383.1366, found: 383.1354.
4h: 1H NMR (400 MHz, DMSO-d6) δ 11.96 (s, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.29 (d, J = 2.2 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 6.49 (d, J = 2.3 Hz, 2H), 6.31 (t, J = 2.3 Hz, 1H), 4.03 (s, 2H), 3.69 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ 160.90, 150.35, 143.78, 139.56 (d, J = 4.1 Hz), 126.79, 124.87, 124.83, 118.70, 116.92 (q, J = 31.5 Hz), 114.52, 107.12, 98.11, 55.50, 31.27. HRMS m/z (ESI) calcd for C17H16N2O2F3 [M + H]+: 337.1158, found: 337.1147.
4i: 1H NMR (400 MHz, DMSO-d6) δ 12.05 (s, 1H), 8.54 (d, J = 2.1 Hz, 1H), 8.34 (d, J = 2.1 Hz, 1H), 7.51 (d, J = 2.3 Hz, 1H), 7.23 (td, J = 9.2, 4.7 Hz, 2H), 7.08 (m, J = 12.2, 8.1, 3.6 Hz, 1H), 4.13 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 159.76, 158.11, 157.37 (d, J = 2.1 Hz), 155.74, 150.21, 139.74, 130.30 (dd, J = 18.6, 7.8 Hz), 127.19, 124.67, 118.46, 114.99, 114.84, 112.55, 49.06, 24.23. HRMS m/z (ESI) calcd for C15H10N2F5 [M + H]+: 313.0759, found: 313.0752.
4j: 1H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 1H), 8.54 (d, J = 2.1 Hz, 1H), 8.36 (d, J = 2.1 Hz, 1H), 7.86 (s, 1H), 7.61 (dd, J = 6.8, 1.9 Hz, 3H), 4.22 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.33, 141.83, 139.80, 134.58, 132.06, 128.60, 128.13, 127.25, 127.04, 124.85, 122.02, 118.49, 117.29 (q, J = 31.7 Hz), 113.62, 29.92. HRMS m/z (ESI) calcd for C16H10N2F6Cl [M + H]+: 379.0430, found: 379.0435.
4k: 1H NMR (400 MHz, DMSO-d6) δ 12.01 (s, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.31 (d, J = 2.1 Hz, 1H), 7.55 (d, J = 2.4 Hz, 1H), 7.38 (d, J = 1.8 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.18 (dd, J = 8.2, 1.7 Hz, 1H), 4.13 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 150.31, 143.24, 141.48, 139.70, 139.68 (d, J = 4.1 Hz), 138.55, 131.61, 126.98, 124.77 (d, J = 4.0 Hz), 124.53, 118.51, 117.22 (q, J = 31.7 Hz), 114.37, 110.63, 110.17, 30.60. HRMS m/z (ESI) calcd for C16H10N2O2F5 [M + H]+: 357.0657, found: 357.0675.
4l: 1H NMR (400 MHz, DMSO-d6) δ 12.02 (s, 1H), 8.53 (d, J = 2.1 Hz, 1H), 8.30 (d, J = 2.1 Hz, 1H), 7.72 (s, 1H), 7.68–7.57 (m, 2H), 7.57–7.46 (m, 2H), 4.23 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 169.35, 164.01, 151.06, 150.37, 148.37, 139.81, 139.60, 138.52, 126.86, 125.20, 124.77 (d, J = 4.4 Hz), 119.08, 117.11 (d, J = 31.6 Hz), 114.90, 110.52, 31.03, 14.52. HRMS m/z (ESI) calcd for C17H13N3OF3 [M + H]+: 332.1005, found: 332.1001.
Free energy of ligand binding:
ΔG = −RT![]() ![]() | (1) |
Binding energy per atom (ligand efficiency):
ΔLE = ΔG/n (non-hydrogen atoms) | (2) |
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra02660g |
‡ These authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2021 |